Peter Hofland is the Executive Editor of 'ADC Review | Journal of Antibody-drug Conjugates,' a comprehensive digital platform and peer reviewed publication focusing on news and information about innovative therapies such as Antibody-drug Conjugates (ADCs). Hofland contributes articles on the advances in ADCs - from initial discovery to approved drug. He is also a the executive editor of 'Onco'Zine', the host 'The Onco'Zine Brief' and the executive producer of 'Changing Strategies in the War of Cancer.' For more information about Hofland, check his ORCID profile here.
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.